Melatonin in Traumatic Brain Injury and Cognition

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Traumatic brain injury (TBI) is a major cause of adult disability and mortality.
• TBI is linked to long-term cognitive deficits and increased risk of neurodegenerative diseases like Alzheimer's.
• Current TBI treatments for cognitive dysfunction lack consistent success in human trials.

Purpose of the Study:

• To review emergent research on melatonin as a potential therapy for TBI.
• To explore melatonin's role in mitigating neuroinflammation and oxidative stress post-TBI.
• To assess melatonin's potential in preventing TBI-related neurodegeneration, including dementia and cognitive decline.

Main Methods:

• Literature review of PubMed using keywords: TBI, melatonin, treatment, dementia, Alzheimer's, cognition, neurodegeneration.
• Included meta-analyses, literature reviews, and randomized controlled trials (RCTs).
• Three independent reviewers assessed 11 selected studies for eligibility.

Main Results:

• Melatonin exhibits significant neuroprotective and anti-inflammatory effects in TBI models.
• Animal studies show melatonin treatment improves cognitive and behavioral outcomes post-TBI.
• Clinical data in humans is scarce, with limited longitudinal studies on dementia risk reduction.

Conclusions:

• Melatonin's anti-inflammatory and antioxidant properties are beneficial in TBI contexts.
• Preclinical data suggests melatonin may reduce post-TBI cognitive decline.
• Further human clinical trials are warranted to evaluate melatonin's efficacy and safety for post-TBI therapy.